相似文献
1
Chronic kidney disease in patients with diabetes mellitus.
Endocr Connect. 2021 Apr 29;10(5):R151-R159. doi: 10.1530/EC-21-0097.
3
Metabolic factors and microinflammatory state promote kidney injury in type 2 diabetes mellitus patients.
Ren Fail. 2009;31(6):470-4. doi: 10.1080/08860220902963822.
4
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".
Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1127-1150. doi: 10.1016/j.numecd.2019.07.017. Epub 2019 Oct 2.
5
Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.
Ont Health Technol Assess Ser. 2015 Sep 1;15(16):1-84. eCollection 2015.
6
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Clin Ther. 2002 Jul;24(7):1019-34. doi: 10.1016/s0149-2918(02)80016-9.
7
Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.
Adv Chronic Kidney Dis. 2018 Mar;25(2):181-191. doi: 10.1053/j.ackd.2017.12.002.
8
Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis.
Endocrine. 2017 Jan;55(1):66-76. doi: 10.1007/s12020-016-1014-6. Epub 2016 Aug 1.
9
Hypertension and diabetes mellitus.
Biomed Pharmacother. 1993;47(2-3):61-6. doi: 10.1016/0753-3322(93)90292-s.
10
Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
Drugs. 2006;66(17):2213-34. doi: 10.2165/00003495-200666170-00005.
引用本文的文献
1
A High-Fat Diet Increases Kidney Fibrosis Through Regulating TGF-β and PDGF-β Signaling Pathways in Normotensive and Hypertensive Rat Models.
Int J Mol Sci. 2025 Aug 20;26(16):8031. doi: 10.3390/ijms26168031.
2
Hypoglycaemic Principles of Extracts Reverses Experimental Diabetes and Diabetes Associated Pathology in Wistar Albino Rats.
Biochem Res Int. 2025 Jul 31;2025:7173019. doi: 10.1155/bri/7173019. eCollection 2025.
3
Dissecting the relationship between heart failure and diabetic retinopathy severity in patients with diabetes and chronic kidney disease: an observational cohort study.
Sci Rep. 2025 Jul 8;15(1):24346. doi: 10.1038/s41598-025-04523-1.
4
Coming of age: could obesity-related metabolic complications be treated by targeting senescent cells?
Front Cell Dev Biol. 2025 Jun 4;13:1622107. doi: 10.3389/fcell.2025.1622107. eCollection 2025.
5
A Nationwide Epidemiological Study of Chronic Kidney Disease Prevalence in a High-Risk Patient Population Without Prior Diagnosis in Primary Health Care in Poland.
J Clin Med. 2025 May 21;14(10):3600. doi: 10.3390/jcm14103600.
6
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease.
Int J Rheum Dis. 2025 May;28(5):e70274. doi: 10.1111/1756-185X.70274.
7
The safety of indocyanine green in patients with advanced chronic kidney disease or kidney transplantation: a scoping review.
Ann Med Surg (Lond). 2024 Nov 18;87(3):1351-1359. doi: 10.1097/MS9.0000000000002713. eCollection 2025 Mar.
8
From fat to filter: the effect of adipose tissue-derived signals on kidney function.
Nat Rev Nephrol. 2025 Apr 2. doi: 10.1038/s41581-025-00950-5.
9
Prevalence of chronic kidney disease in Saudi Arabia: an epidemiological population-based study.
BMC Nephrol. 2025 Jan 24;26(1):37. doi: 10.1186/s12882-025-03954-2.
10
Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review.
Cureus. 2024 Dec 20;16(12):e76101. doi: 10.7759/cureus.76101. eCollection 2024 Dec.
本文引用的文献
1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
2
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m: Subgroup Analysis of the Randomized CREDENCE Trial.
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19.
3
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
4
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
J Diabetes Res. 2020 Aug 8;2020:2984680. doi: 10.1155/2020/2984680. eCollection 2020.
8
Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results.
Diabetes Ther. 2020 Sep;11(9):1983-1999. doi: 10.1007/s13300-020-00888-w. Epub 2020 Aug 5.
9
Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis.
Ann Intern Med. 2020 Sep 15;173(6):426-435. doi: 10.7326/M20-0529. Epub 2020 Jul 14.
10
Bardoxolone methyl: drug development for diabetic kidney disease.
Clin Exp Nephrol. 2020 Oct;24(10):857-864. doi: 10.1007/s10157-020-01917-5. Epub 2020 Jun 27.
Zotero 插件